| OAB0203 | Optimal timing for ART initiation in ART-naive children and adolescents living with HIV following the diagnosis of HIV-associated TB | Oral abstract session with live Q&A | TB/HIV co-infection in paediatric and adolescent populations (including treatment and prevention) |
| OAB0204 | Subcortical brain volumes of children who are HIV-exposed and uninfected in the first three years of life: a South African birth cohort study | Oral abstract session with live Q&A | HIV-exposed uninfected children |
| OAB0205 | Probability of AIDS and non-AIDS-related mortality of early-treated children living with HIV-1 | Oral abstract session with live Q&A | ARV management strategies in paediatric and adolescent populations |
| OAB0302 | Efficacy and safety of dolutegravir plusemtricitabinevs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0303 | Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0304 | Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0305 | Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0402 | Efficacy and safety results in participants co-infected with HIV from TB-PRACTECAL Clinical Trial | Oral abstract session with live Q&A | Tuberculosis: Prevention, diagnosis, treatment |
| OAB0403 | Impact of a community-wide HIV test and treat intervention on population-level tuberculosis transmission in rural Uganda | Oral abstract session with live Q&A | Tuberculosis: Prevention, diagnosis, treatment |
| OAB0404 | Are people living with HIV at higher risk of severe and fatal COVID-19? | Oral abstract session with live Q&A | Clinical manifestations and features of COVID-19 and HIV co-infection |